Skip to content

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Neoplasms

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    0 and up

Critères de participation

Inclusion Criteria:

* Participants who have received at least one dose of ADP adoptive cell therapy agent.
* Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
* Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* The investigator is responsible for review of medical history.
* Capable of giving signed informed consent.

Exclusion Criteria:

- None

Lieu de l'étude

Hôpital Maisonneuve-Rosemont
Hôpital Maisonneuve-Rosemont
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Adaptimmune Patient Enquiries

[email protected]
215-825-9260
Princess Margaret Cancer Centre
Princess Margaret Cancer Centre
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Adaptimmune Patient Enquiries

[email protected]
215-825-9260
Étude parrainée par
Adaptimmune
Participants recherchés
Plus d'informations
ID de l'étude: NCT03391778